Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Ado-Trastuzumab Emtansine’s Impact
J Clin Oncol; 2016 Oct 10; Dzimitrowicz, et al
Ado-trastuzumab emtansine (T-DM1) may be beneficial in women with HER2-positive metastatic breast cancer who received prior pertuzumab, according to a study involving 78 individuals.
Investigators looked at treatment sequencing and outcomes in patients treated at 3 academic medical center hospitals. Among the results:
- ~One-third received T-DM1 as first- and second-line line therapy; it was given to ~half as fourth-line treatment or later.
- 3 in every 10 experienced duration of therapy ≥ 6 months.
- Tumor response rate was 18%.
- Patients stayed on therapy for a median of 4 months.
- The medication was stopped due to disease progression in 84%, and toxicity in 10%.
Citation:
Dzimitrowicz H, Berger M, Vargo C, et al. T-DM1 activity in metastatic human epidermal growth factor receptor 2–positive breast cancers that received prior therapy with trastuzumab and pertuzumab. J Clin Oncol. 2016;34(29):3511-3517. doi: 10.1200/JCO.2016.67.3624.